1 Sofosbuvir and ribavirin for genotype 2 HCV infected patients with cirrhosis: A real life experience.

2 Prediction of efficacy to pegylated interferon-α-2b plus ribavirin in patients with genotype 2 hepatitis C virus using viral response within 2 weeks.

3 treatment of chronic hepatitis c among injecting drug users: a 5-year follow-up

4 evaluation of factors associated with relapse in telaprevir-based triple therapy for chronic hepatitis c

5 efficacy of interferon alpha- 2b with or without ribavirin in thalassemia major patients with chronic hepatitis c virus infection: a randomized, double blind, controlled, parallel group trial

6 very-low-dose pegylated interferon α2a plus ribavirin therapy for advanced liver cirrhosis type c: a possible therapeutic alternative without splenic intervention

7 potential of g-csf supplementation to counter the neutrophil effects of standard peg-ifnα plus ribavirin combination therapy for treating hcv-related cirrhosis

8 Grazoprevir/elbasvir in peginterferon alfa plus ribavirin experienced patients with chronic genotype 1 HCV/HIV co-infection: a non-randomized, open-label clinical trial

9 Outcomes and predictors of treatment response with sofosbuvir plus daclatasvir with or without ribavirin in Egyptian patients with genotype 4 hepatitis C virus infection

10 Pegylated-interferon plus ribavirin treatment does not alter the prevalence of resistance-associated substitutions to direct-acting antivirals in HCV genotype 1a patients

11 Grazoprevir/elbasvir in peginterferon alfa plus ribavirin experienced patients with chronic genotype 1 HCV/HIV co-infection: a non-randomized, open-label clinical trial

12 Outcomes and predictors of treatment response with sofosbuvir plus daclatasvir with or without ribavirin in Egyptian patients with genotype 4 hepatitis C virus infection

13 Pegylated-interferon plus ribavirin treatment does not alter the prevalence of resistance-associated substitutions to direct-acting antivirals in HCV genotype 1a patients

14 Development and validation of a versatile HPLC-DAD method for simultaneous determination of the antiviral drugs daclatasvir, ledipasvir, sofosbuvir and ribavirin in presence of seven potential impurities. Application to assay of dosage forms and dissolution studies

15 Real-world safety and effectiveness of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C virus genotype 1- and 4-infected patients with diverse comorbidities and comedications: A pooled analysis of post-marketing observational studies from 13 countries

16 Association of ITPA gene variation and serum ribavirin concentration with a decline in blood cell concentrations during pegylated interferon-alpha plus ribavirin therapy for chronic hepatitis C.

17 Cost-Effectiveness Analysis of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with or without Ribavirin Regimen for Patients Infected with Chronic Hepatitis C Virus Genotype 1 in Malaysia

18 Respiratory syncytial virus upper respiratory tract illnesses in adult blood and marrow transplant recipients: combination therapy with aerosolized ribavirin and intravenous immunoglobulin

19 Long term follow-up of children hospitalized with respiratory syncytial virus lower respiratory tract infection and randomly treated with ribavirin or placebo

20 Ribavirin therapy: implementation of hospital guidelines and effect on usage and cost of therapy

21 Ribavirin aerosol for acute bronchiolitis

22 Respiratory syncytial virus infections in autologous blood and marrow transplant recipients with breast cancer: combination therapy with aerosolized ribavirin and parenteral immunoglobulins

23 Ribavirin aerosol for acute bronchiolitis.

24 Phase I study of intravenous ribavirin treatment of respiratory syncytial virus pneumonia after marrow transplantation.

25 Aerosolized ribavirin in mechanically ventilated children with respiratory syncytial virus lower respiratory tract disease: a prospective, double-blind, randomized trial

26 Phase I study of intravenous ribavirin treatment of respiratory syncytial virus pneumonia after marrow transplantation

27 Ribavirin for respiratory syncytial virus lower respiratory tract infection. A systematic overview

28 Reassessment of the indications for ribavirin therapy in respiratory syncytial virus infections. American Academy of Pediatrics Committee on Infectious Diseases

29 Respiratory syncytial virus upper respiratory tract illnesses in adult blood and marrow transplant recipients: combination therapy with aerosolized ribavirin and intravenous immunoglobulin

30 Effectiveness of ribavirin in otherwise well infants with respiratory syncytial virus-associated respiratory failure. Pediatric Critical Study Group

31 Effect of ribavirin therapy on respiratory syncytial virus-specific IgE and IgA responses after infection

32 A controlled trial of aerosolized ribavirin in infants receiving mechanical ventilation for severe respiratory syncytial virus infection

33 Ribavirin treatment of respiratory syncytial viral infection in infants with underlying cardiopulmonary disease

34 Immunoglobulin administration and ribavirin therapy: efficacy in respiratory syncytial virus infection of the cotton rat

35 Historical cohort evaluation of ribavirin efficacy in respiratory syncytial virus infection

36 Does ribavirin impact on the hospital course of children with respiratory syncytial virus (RSV) infection? An analysis using the pediatric investigators collaborative network on infections in Canada (PICNIC) RSV database

37 Follow-up of children with respiratory syncytial virus bronchiolitis in 1986 and 1987: potential effect of ribavirin on long term pulmonary function. The Bronchiolitis Study Group

38 Ribavirin aerosol treatment of bronchiolitis associated with respiratory syncytial virus infection in infants

39 Combination therapy with aerosolized ribavirin and intravenous immunoglobulin for respiratory syncytial virus disease in adult bone marrow transplant recipients

40 Early ribavirin treatment of respiratory syncytial viral infection in high-risk children

41 Respiratory syncytial virus infections in autologous blood and marrow transplant recipients with breast cancer: combination therapy with aerosolized ribavirin and parenteral immunoglobulins

42 Aerosolized ribavirin in the treatment of patients with respiratory syncytial virus disease

43 Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. A randomized double-blind study

44 on-treatment elevation in hepatic transaminases during hcv treatment with ombitasvir, paritaprevir, dasabuvir, ritonavir, and ribavirin: a case series

45 arenaviruses and lethal mutagenesis. prospects for new ribavirin-based interventions

46 comparative efficacy of combined treatment with intron a and pegintron in combination with ribavirin in patients with chronic hepatitis С

47 pegylated-interferon alpha 2b and ribavirin for recurrent hepatitis c after liver transplantation: from a canadian experience to recommendations for therapy

48 the treatment outcome and impact on blood transfusion demand of peg-interferon/ribavirin in thalassemic patients with chronic hepatitis c

49 increased oral lichen planus in a chronic hepatitis patient associated with elevated transaminase levels before and after interferon/ribavirin therapy

50 boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis c virus genotype 1 in hiv–hcv co-infected patients: final results of the spanish boc hiv–hcv study

51 retreatment with pegylated interferon alpha-2a and ribavirin in patients with chronic hepatitis c who have relapsed or not responded to a first course of pegylated interferon-based therapy

52 efficacy and safety of low-dose peginterferon alpha-2a plus ribavirin on chronic hepatitis c

53 response to pegylated interferon plus ribavirin in patients with hepatitis c virus genotype 6a infection from guangdong and guangxi province of china

54 effect of iron overload on the severity of liver histologic alterations and on the response to interferon and ribavirin therapy of patients with hepatitis c infection

55 Pegylated Interferon-α-2a plus Ribavirin for Treatment-Naive Asian Patients with Hepatitis C Virus Genotype 1 Infection: A Multicenter, Randomized Controlled Trial

56 Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials

57 In vitro and in vivo sensitivity of a non-mouse-adapted influenza A (Beijing) virus infection to amantadine and ribavirin

58 Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial

59 Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses

60 Telaprevir for HIV/Hepatitis C Virus–Coinfected Patients Failing Treatment With Pegylated Interferon/Ribavirin (ANRS HC26 TelapreVIH): An Open-Label, Single-Arm, Phase 2 Trial

61 The influence of hepatitis B virus on antiviral treatment with interferon and ribavirin in Asian patients with hepatitis C virus/hepatitis B virus coinfection: a meta-analysis

62 A severe hepatitis flare in an HBV-HCV coinfected patient during combination therapy with alpha-interferon and ribavirin

Keyword Connections

Journals

Research Groups

Bibliographies